Evaxion

Executive Summary

Evaxion is a private Danish biotechnology company leveraging its proprietary AI-Immunology platform to develop personalized and precision vaccines for cancer and infectious diseases. The platform integrates multiple AI prediction models tailored to address complex immune-related healthcare challenges, enabling the rapid design of novel vaccine candidates. Founded in 2021 and currently in Phase 2 development, Evaxion aims to transform vaccine development through artificial intelligence, potentially reducing time and costs compared to traditional approaches. While the company has not disclosed total funding or valuation, its focus on AI-driven drug discovery positions it within a rapidly growing sector. The lack of publicly available pipeline details suggests an early clinical stage with limited near-term revenue visibility, but its innovative platform could attract strategic partnerships or financing as it advances toward proof-of-concept data.

Upcoming Catalysts (preview)

• TBDPhase 2 clinical data readout for lead vaccine candidate40% success
• TBDAnnouncement of strategic partnership or licensing deal50% success
• TBDClosing of Series A or B funding round60% success